Mustang Bio, Inc.
MBIOHealthcare|Biotechnology|US
$0.39
+0.00 (+0.15%)
DCF Value
$2.93
Tangible Book / Share
$0.98
Cash / Share
$2.12
Clinical Trials (5)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT03277729 A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas | Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | P1P2 | Active | 53 | Open-label | Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate |
| NCT02159495 Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm | Adult Acute Myeloid Leukemia in Remission, Acute Biphenotypic Leukemia | P1 | Active | 31 | Open-label | cyclophosphamide, Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes, Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes, Fludarabine Phosphate |
| NCT04109482 Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN. | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | P1P2 | Terminated | 3 | Open-label | MB-102, Fludarabine, Cyclophosphamide |
| NCT05360238 Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL | Follicular B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma Recurrent | P1P2 | Terminated | 20 | Open-label | MB-106 |
| NCT05645744 Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product. | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Chronic Lymphocytic Leukemia in Relapse | Terminated | 3 | — | Prior MB-102 CAR-T cell investigational product., Prior MB-106 CAR-T cell investigational product. |